AI Article Synopsis

  • This study investigates the impact of pathological lymph node (LN) regression after neoadjuvant chemotherapy on survival rates in patients with esophageal adenocarcinoma, addressing a gap in existing research and defining LN response classifications.
  • Conducted across five UK centers, the study analyzed 17,930 LNs from 763 patients, assigning scores based on the extent of residual tumor found in the nodes after treatment, with survival outcomes assessed using advanced statistical methods.
  • Results showed that patients with complete or partial LN response had significantly lower mortality rates compared to those with poor or no LN response, highlighting LN regression as a vital prognostic factor that should be considered alongside traditional staging methods.

Article Abstract

Purpose: There is limited evidence regarding the prognostic effects of pathologic lymph node (LN) regression after neoadjuvant chemotherapy for esophageal adenocarcinoma, and a definition of LN response is lacking. This study aimed to evaluate how LN regression influences survival after surgery for esophageal adenocarcinoma.

Methods: Multicenter cohort study of patients with esophageal adenocarcinoma treated with neoadjuvant chemotherapy followed by surgical resection at five high-volume centers in the United Kingdom. LNs retrieved at esophagectomy were examined for chemotherapy response and given a LN regression score (LNRS)-LNRS 1, complete response; 2, <10% residual tumor; 3, 10%-50% residual tumor; 4, >50% residual tumor; and 5, no response. Survival analysis was performed using Cox regression adjusting for confounders including primary tumor regression. The discriminatory ability of different LN response classifications to predict survival was evaluated using Akaike information criterion and Harrell C-index.

Results: In total, 17,930 LNs from 763 patients were examined. LN response classified as (LNRS 1 ≥1 LN, no residual tumor in any LN; n = 62, 8.1%), (LNRS 1-3 ≥1 LN, residual tumor ≥1 LN; n = 155, 20.3%), (LNRS 4-5; n = 303, 39.7%), or (no tumor/regression; n = 243, 31.8%) demonstrated superior discriminatory ability. Mortality was reduced in patients with complete LN response (hazard ratio [HR], 0.35; 95% CI, 0.22 to 0.56), partial LN response (HR, 0.72; 95% CI, 0.57 to 0.93) or negative LNs (HR, 0.32; 95% CI, 0.25 to 0.42) compared with those with poor/no LN response. Primary tumor regression and LN regression were discordant in 165 patients (21.9%).

Conclusion: Pathologic LN regression after neoadjuvant chemotherapy was a strong prognostic factor and provides important information beyond pathologic TNM staging and primary tumor regression grading. LN regression should be included as standard in the pathologic reporting of esophagectomy specimens.

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.23.00139DOI Listing

Publication Analysis

Top Keywords

neoadjuvant chemotherapy
16
regression neoadjuvant
12
esophageal adenocarcinoma
12
residual tumor
12
primary tumor
12
tumor regression
12
regression
11
response
9
pathologic lymph
8
lymph node
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!